GLP-1 Stopping Timeline Tool (Wegovy, Ozempic, Mounjaro)

If you’re planning to stop semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro), the hardest part is often what happens after the last injection: appetite returns, routines drift, and weight regain can feel “inevitable”.

This page gives you a simple, educational timeline based on your last dose date—plus a practical maintenance plan you can actually follow.

UK note: If you’re prescribed via the NHS or privately, it’s still worth having a structured plan for the first 12 weeks after stopping, because this is when behaviour tends to slide.

How to use the tool

  1. Choose your medication (Wegovy/Ozempic or Mounjaro).

  2. Enter the date of your last injection.

  3. Read your timeline and use the “Focus” actions for each phase.

What you’ll get: a week-by-week guide to what many people report (appetite, cravings, GI changes, energy/training), and what to prioritise next.

What you won’t get: personalised medical advice, dosing instructions, or diagnosis.

Important safety notes (please read)

This tool is educational. It does not replace care from your prescriber.

Speak to your clinician before stopping if any of the following apply

  • You have type 2 diabetes, use insulin or sulfonylureas, or your glucose control is unstable (stopping can change glycaemic control and may require monitoring/medication adjustment).

  • You are pregnant, trying to conceive, or breastfeeding.

  • You have a history of pancreatitis or severe gastrointestinal disease.

  • You feel unwell, dehydrated, or have persistent vomiting.

Seek urgent help now if you have

Severe abdominal pain (especially with vomiting), fainting, confusion, or signs of severe dehydration.

GLP-1 stopping timeline

Enter your last dose details to see an educational, general timeline of what people often notice and what to focus on next.

Educational tool only. Not medical advice. If you feel unwell, are pregnant, or have diabetes/complex conditions, speak to your clinician.

Your timeline

What people often notice around now
    What to focus on this week

      Stay up to date

      Get occasional updates when I publish new guidance on coming off GLP-1s, SSRIs, PPIs, statins and other common medicines, including metabolic consequences and practical solutions. Just enter your details below

      WHY TIMING MATTERS

      Half life is plain English.

      graph of the half life of tirzepatide and semaglutide

      These medications don’t disappear overnight.

      • Semaglutide (Wegovy/Ozempic) has a long half-life of about 1 week, so effects can fade gradually.

      • Tirzepatide (Mounjaro) has a half-life of about 5 days.

      That’s why some people feel “fine” for a week or two and then suddenly notice appetite and cravings accelerating.

      WHAT TO EXPECT

      A practical “what to expect” timeline (generic version).

      (Your personalised timeline appears above once you enter your date. This is the general pattern many people recognise.)

      • Phase 1: Weeks 1–2 after the last dose

        Common experiences

        • Appetite starts to rise in the background (often subtle).
        • Food noise creeps back.
        • Some people notice bowel habit changes as appetite and volume of food increase.

        Focus this week

        • Keep your meal structure steady (avoid “winging it”).
        • Aim for protein at each meal and fibre daily.
        • Hydration + regular walking (simple, boring, effective).

      • Phase 2: Weeks 3–6

        Common experiences

        • Appetite is more noticeable; cravings become more specific (snacks, sweets, late-night eating).
        • Portions drift upward without you realising.
        • Training can feel harder if you’re under-sleeping or under-proteining.

        Focus this phase

        • Use a repeatable meal template (same breakfast/lunch most days).
        • Plan two high-risk moments (evenings, weekends, social events).
        • Strength train 2–3×/week if possible (or restart gently).

      • Phase 3: Weeks 6–12

        Common experiences

        • This is where regain often accelerates if habits haven’t been rebuilt.
        • People feel frustrated: “I’m doing the same things, but it’s not working.”

        Focus this phase

        • Tighten the basics: protein, fibre, steps, sleep, alcohol.
        • Track one simple metric (weight trend or waist), not everything.
        • Consider a structured check-in (coach/clinician) if you’re slipping.

      • Beyond 3 months

        Common experiences

        • Some maintain well with a stable routine.
        • Others drift gradually and only notice after a few months.

        Focus long-term

        • Build a “minimum effective routine” you can do even in busy weeks.
        • If weight regain is significant and distressing, discuss options with your prescriber.

      In clinical trials, many participants regained a substantial proportion of lost weight after stopping GLP-1 therapy.

      • In the STEP 1 extension, people regained about two-thirds of prior weight loss one year after stopping semaglutide (on average), alongside reversal toward baseline of several cardiometabolic improvements. [1]

      • In SURMOUNT-4, participants who stopped tirzepatide and switched to placebo regained significant weight compared with those who continued. [2]

      Takeaway: obesity and appetite regulation behave like a chronic biology + environment problem. If you’re stopping, your plan needs to be at least as structured as the medication was.

      THE BIG REALITY

      Regain risk is real and it’s not a moral failure.

      MAINTENANCE PLAN

      A simple, effective, and non-obsessive approach to use as a default week.

      • 1) Protein + fibre anchors (most bang for buck)

        • Protein at each meal.
        • A fibre source daily (veg, beans, berries, oats, whole grains, whatever you tolerate).

      • 2) Meal structure beats willpower

        Pick a structure you can repeat:

        • 2–3 meals/day, fewer “grazing” moments.
        • A planned snack if evenings are your danger zone.

      • 3) Strength training protects you

        Aim for 2–3 sessions/week (even 20–30 minutes). If you can’t: do a minimum plan (push/pull/legs basics or bodyweight circuits).

      • 4) Steps and sleep are appetite tools

        Walking reduces stress-driven eating for many people; sleep loss increases appetite drive and cravings.

      • 5) Alcohol: the stealth lever

        If weekends undo your week, start here. Reduce frequency or set a simple cap.

      • 6) Track just enough

        Choose one:

        1. Weekly average weight trend, or
        2. Waist measurement every 2–4 weeks

        If tracking makes you spiral, don’t do it.

      WHO THIS TOOL IS FOR

      • This is for you if:

        • You’re stopping Wegovy/Ozempic/Mounjaro and want a structured plan

        • You’ve already stopped and feel appetite/weight is rebounding

        • You want a practical way to reduce regain risk over the next 12 weeks

      • This tool is not for:

        • Managing acute symptoms

        • Individual prescribing decisions

        • Diabetes medication changes without clinician input

      FAQ

      The practical questions — answered clearly.

      • Some people stop abruptly; others step down. The right approach depends on why you’re stopping (side effects, cost, pregnancy planning, response, diabetes control). If you have diabetes or are on other glucose-lowering meds, discuss a plan with your clinician. [3]

      • Because these drugs have long half-lives, appetite often returns gradually over weeks, not overnight. Semaglutide is ~1 week half-life; tirzepatide ~5 days. [4]

      • Not inevitable, but risk is higher if routine slips. Trials show substantial regain after withdrawal for many people, which is why a maintenance plan matters. [1]

      • For most people: meal structure (planned meals, less grazing) + protein anchors + strength training. If you only do one thing, build a repeatable week.

      • No. Appetite drive is biology plus environment. This is exactly why people struggle after stopping, and why “just try harder” is a weak strategy.

      • Persistent vomiting, severe abdominal pain, dehydration, or escalating symptoms need medical review. If symptoms are mild, focus on hydration and gentle foods, then get clinician advice if they persist.

      CLINICAL LEAD

      A doctor who understands physiology and what people can actually sustain.

      A man with a beard and blue eyes, wearing a light blue striped button-up shirt, smiling in front of a wooden panel background.

      I continue to work in the NHS A&E and privately specialise in the gap between intention and reality, building systems that make change stick. My background spans clinical medicine, sports performance, education, and health technology, translating physiology into outcomes you can repeat.

      This tool is designed to be practical and patient-friendly, and is updated as new evidence emerges.

      NHS A&E doctor — frontline clinical reality

      Founder + medical advisor — systems, strategy, outcomes

      Public educator — media, podcasts, international speaking

      Learn more about Dr Dan

      References

      1. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252. https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252

      2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945 https://jamanetwork.com/journals/jama/fullarticle/2812936

      3. FDA prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf

      4. FDA prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf

      BOOK AN APPOINTMENT

      If you want clinician-led clarity on medications, metabolic health, or both, book via Sutton Medical Consulting.

      Call: 0121 308 7774

      Email: admin.team@suttonmed.co.uk

      Book an appointment

      Clinical appointments are provided by CQC-registered Sutton Medical Consulting